Please login to the form below

Not currently logged in
Email:
Password:

GlycoVaxyn appoints Gerd Zettlmeissl as chairman

He will join the Swiss vaccines company in June

Swiss vaccines company GlycoVaxyn has appointed Gerd Zettlmeissl as chairman of the board of directors with effect from June, when he will take over from Michel Greco.

"Having worked very closely with Gerd at Intercell for a number of years, I am convinced that he will bring a wealth of development experience and entrepreneurial spirit to this very promising company," Greco said.

"Having chaired the board for more than seven years, I will work very closely with Gerd to ensure a smooth transition," he added.

Zettlmeissl has more than 20 years of experience in developing and commercialising vaccines and spent almost 10 years in executive positions at Intercell.

He served first as its chief operating officer from 2001 to 2005 and then as CEO from 2005 until May  2011.

Prior to joining Intercell, Zettlmeissl served as international head of industrial and quality operations at Chiron Vaccines, and managing director of Chiron Behring GmbH & Co.

He currently serves on the boards of several biotechnology companies including Aeras, an organisation dedicated to the development of tuberculosis vaccines.

6th March 2013

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....